Temperature-Sensitive Multivalent LAIV for Equine H3N8 Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current equine influenza vaccines, particularly those based on inactivated or existing live attenuated influenza vaccines, fail to provide adequate protection against antigenically diverse H3N8 equine influenza virus strains, leading to frequent outbreaks and significant economic losses due to mismatched strains and rapid antigenic variation.
Innovation Solution
Development of a multivalent live-attenuated influenza vaccine (LAIV) comprising mutations in segments 1 and 2 of the EIV genome, specifically in PB2 and PB1 proteins, rendering the virus temperature-sensitive, allowing it to induce robust immune responses while reducing replication at normal and elevated body temperatures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional inactivated or live attenuated influenza vaccines are used, then vaccination can be administered, but they provide poor protection against antigenically diverse H3N8 equine influenza virus strains due to antigenic mismatch
Solution Approach 1:
The vaccine composition includes multiple LAIV strains (at least two) representing different clades (clade 1 and clade 2) of H3N8 EIV, enabling the vaccine to provide broad protection against antigenically diverse strains. This multivalent approach makes the vaccine universally effective across different viral variants without requiring separate vaccinations for each strain.
Solution Approach 2:
The patent introduces specific mutations in the PB2 and PB1 proteins of the influenza virus genome (segments 1 and 2) to create temperature-sensitive live-attenuated vaccines. These parameter changes in the viral genome allow the vaccine strains to replicate efficiently at lower temperatures (inducing strong immune responses) while being attenuated at body temperature, providing reliable protection across different clades.
2Reliability
If vaccine strains are updated frequently to match circulating viruses, then protection against current strains improves, but vaccine development time and complexity increase
Solution Approach 1:
The vaccine composition proactively includes multiple LAIV strains representing both clade 1 and clade 2 H3N8 EIV in a single formulation. This preliminary inclusion of diverse strains eliminates the need for frequent vaccine updates and strain selection, as the multivalent composition already covers multiple antigenic variants simultaneously, saving time in vaccine development and deployment.
3Adaptability or versatility
If multiple separate vaccinations are administered to cover different strains, then broader protection is achieved, but the number of doses and vaccination complexity increase
Solution Approach 1:
The patent combines multiple live-attenuated influenza virus strains (at least two LAIVs from different clades) into a single multivalent vaccine composition. This merging of multiple strains into one formulation provides broad protection against antigenically diverse H3N8 EIV strains while simplifying the vaccination regimen to a single administration, reducing complexity compared to multiple separate vaccinations.
4Reliability
If live-attenuated vaccines are used to induce strong immune responses, then immunity is enhanced, but replication at normal body temperature may cause safety concerns
Solution Approach 1:
The patent introduces specific mutations in the PB2 and PB1 proteins (segments 1 and 2 of the viral genome) to create temperature-sensitive phenotypes. These parameter changes allow the vaccine viruses to replicate robustly at lower temperatures (inducing strong innate and adaptive immune responses) while being naturally attenuated at normal equine body temperature, thereby enhancing immunity without compromising safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multivalent LAIV effectively induces both innate and adaptive immune responses, providing superior protection against multiple H3N8 strains, reducing the frequency of outbreaks, and requiring fewer doses compared to traditional vaccines, with improved cross-protection against antigenically distinct strains.
Implementation Method 1
comprising mutations in segments 1 and 2 of the EIV genome, specifically in PB2 and PB1 proteins, rendering the virus temperature-sensitive, allowing it to induce robust immune responses while reducing replication at normal and elevated body temperatures
Data Source
AI summary
The present invention provides compositions and methods related to equine live-attenuated influenza vaccines. In one aspect, the invention relates to a composition comprising a multivalent equine live-attenuated influenza vaccine comprising a first live-attenuated influenza virus expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and a second live-attenuated influenza virus expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second live-attenuated influenza virus expresses HA, NA, or a combination thereof of A/equine/Lancashire/1/2016 H3N8.